This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Lyell Immunopharma (LYEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
by Zacks Equity Research
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
by Zacks Equity Research
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
by Zacks Equity Research
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Lyell Immunopharma (LYEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
by Zacks Equity Research
Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 175% and 0.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of 0% and 11.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Catalyst Pharmaceuticals (CPRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and Lyell Immunopharma (LYEL) have performed compared to their sector so far this year.
Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 91%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 91% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 90%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Lyell Immunopharma (LYEL) points to a 90% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can Lyell Immunopharma (LYEL) Climb 93% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Lyell Immunopharma (LYEL) points to a 93.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech ETF Tops in June: 5 Stocks That Outperform
by Sweta Killa
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.